Balancing potency and safety in T-cell-engaging bispecific antibodies for solid tumors
03 Nov 2026
Bi/Multispecifics
- Why potent T-cell activation often comes at the cost of increased cytokine release.
- Strategies to improve the therapeutic window while maintaining robust antitumor efficacy.
- Challenges in translating promising preclinical activity into meaningful clinical benefit for solid tumors.
- The impact of antibody format and molecular design on immune synapse formation and T-cell function.
- Emerging approaches to developing safer and more effective T-cell-engaging bispecific antibodies.
Industry Expert
